FDA’s Cardio-Renal Division Kicks Off August With Three Approvals
The Medicines Co.’s IV therapy Cleviprex plus Novartis’ drug-drug combos, Exforge and Diovan HCT, are approved.
The Medicines Co.’s IV therapy Cleviprex plus Novartis’ drug-drug combos, Exforge and Diovan HCT, are approved.